Invention Grant
- Patent Title: Treatment for rheumatoid arthritis
-
Application No.: US15880726Application Date: 2018-01-26
-
Publication No.: US10913792B2Publication Date: 2021-02-09
- Inventor: Stefan Hartle , Stephane Leclair , Amgad Shebl , Stefan Steidl , Bodo Brocks , Daniela Della Ducata , Kai Rosport
- Applicant: MORPHOSYS AG
- Applicant Address: DE Planegg
- Assignee: MORPHOSYS AG
- Current Assignee: MORPHOSYS AG
- Current Assignee Address: DE Planegg
- Agency: Foley & Lardner LLP
- Priority: EP12185235 20120920
- Main IPC: C07K16/24
- IPC: C07K16/24 ; A61K31/519 ; A61K39/395 ; A61K39/00
Abstract:
The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.
Public/Granted literature
- US20180230208A1 TREATMENT FOR RHEUMATOID ARTHRITIS Public/Granted day:2018-08-16
Information query
